SCHEMBL4417441

SCHEMBL4417441

CS(=O)(=O)c1nc(OCC(F)(F)F)c(C#N)c(N2CCC(c3ccc(F)cc3)CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 5/20 0.41
PIK3CD O00329 1/20 0.39
TRPV1 Q8NER1 1/20 0.37
AOC3 Q16853 3/20 0.36
RPS6KB1 P23443 3/20 0.35
AKT1 P31749 3/20 0.35
AKT2 P31751 1/20 0.35
KCNH2 Q12809 1/20 0.35
AKT3 Q9Y243 1/20 0.35
LMNA P02545 2/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4417486 0.92 GRM2 (0.43) GRM2PIK3CD
SCHEMBL4424135 0.84 GRM2 (0.42) GRM2PIK3CDAOC3RPS6KB1AKT1
SCHEMBL6957239 0.80 PIK3CD (0.40) GRM2PIK3CDTRPV1KCNH2LMNA
SCHEMBL4417479 0.79 GRM2 (0.40) GRM2PIK3CDTRPV1AOC3RPS6KB1
SCHEMBL4420371 0.76 GRM2 (0.45) GRM2PIK3CDRPS6KB1AKT1AKT2
SCHEMBL4413537 0.75 OGA (0.40) GRM2LMNAHPGDKDM4EALDH1A1
SCHEMBL4420340 0.70 GRM2 (0.42) GRM2TRPV1AOC3RPS6KB1AKT1
SCHEMBL4417537 0.70 GRM2 (0.42) GRM2PIK3CDMEN1GAAKMT2A
SCHEMBL4422651 0.68 KDM4E (0.42) GRM2KDM4EMEN1ALDH1A1GAA
SCHEMBL4413452 0.67 GRM2 (0.41) GRM2LMNAHPGDKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397351-B1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS HOFFMANN LA ROCHE (CH) 2009-11-11 EP disclosed
EP-1397351-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2004-03-17 EP disclosed
US-6673795-B2 SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. 2004-01-06 US disclosed
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-03-27 US disclosed
WO-2002098864-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives P2RX5, IL5, P2RX2 GRM2 441/4885PIK3CD 2052/4885TRPV1 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.